Straits Times Index
3,292.69 +10.64 (+0.32%) S&P 500
5,018.39 -17.30 (-0.34%) Dow
37,903.29 +87.37 (+0.23%) Nasdaq
15,605.48 -52.34 (-0.33%) Bitcoin USD
57,986.41 -2,942.90 (-4.83%) CMC Crypto 200
1,271.08 -67.98 (-5.08%)
Eton Pharmaceuticals, Inc. (ETON)
| Previous close | 3.5000 |
| Open | 3.6000 |
| Bid | 2.6500 x 200 |
| Ask | 4.5600 x 200 |
| Day's range | 3.5400 - 3.7500 |
| 52-week range | 2.4200 - 5.8100 |
| Volume | |
| Avg. volume | 60,970 |
| Market cap | 94.532M |
| Beta (5Y monthly) | 1.18 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireEton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference in New York as follows: Date:Monday, May 13, 2024 Time: 10:00am ET Webcast: Click Here To schedule a 1x1 meeting with the Company, plea
- GlobeNewswire
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak sales of more than $50 million annually -- Product has patent protection through 2043 - DEER PARK, Ill., April 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission
- GlobeNewswire
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Register* (Audio Only) Click Here In addition to takin
